CymaBay Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

CymaBay Therapeutics

15/05/2023 22:46

* CymaBay Therapeutics Inc  CBAY.OQ  reported a quarterly
adjusted
loss of 29 cents​​ per share for the quarter ended in March. The
mean expectation of nine analysts for the quarter was for a loss
of 9 cents per share.
    * Reported revenue was zero​; analysts expected $21.35
million. 
    * CymaBay Therapeutics Inc's reported EPS for the quarter
was a
loss of 29 cents​.
    * The mean earnings estimate of analysts had risen by
about 46.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * CymaBay Therapeutics Inc shares had risen by 17.5% this
quarter and gained 63.5% so far this year.
    * The company reported a quarterly loss of $28.78 million.
    * Wall Street's median 12-month price target for CymaBay
Therapeutics Inc is $13.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
15 at 09:46 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.09          -0.29          Missed
 Dec. 31 2022      -0.30          -0.30          Met
 Sep. 30 2022      -0.30          -0.28          Beat
 Jun. 30 2022      -0.30          -0.31          Missed